Composition of novel carbohydrate drug for treatment of human diseases

A method comprising:

• a. obtaining a composition for parenteral or enteral administration, the composition comprising a complex carbohydrate backbone of 1,4-linked galacturonic acid (GalA) and 1,4-linked methyl galacturonate (MeGalA) residues with interspersed α-1,2 linked rhamnose within the carbohydrate backbone, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof,
• wherein the molar percent of the oligomers of 1,4-β-D-galactose residues and 1,5-α-L-arabinose residues is greater than 10% of the total carbohydrate molar content,
• wherein the compound has a degree of methoxylation ranging from 33% to 66%, and
• wherein the 1,4-β-D-galactose and 1,5-α-L-arabinose residues are present in a 2:1 to a 3:1 ratio;
• and
• b. administering to a subject in need thereof an effective dose of the composition to a subject in need thereof, wherein administration results in at least a 10% reduction in clinical symptoms and complications resulting from liver fibrosis and cirrhosis.